Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Alrex safe for long-term treatment of seasonal allergic conjunctivitis

Feb. 24, 2004

Senju claims new chymase and/or tryptase inhibitors and their use

Feb. 11, 2004

Extension to Vitrase NDA review

Feb. 10, 2004

Inspire to conduct additional trial for diquafosol following FDA meeting

Feb. 4, 2004

Phase III data for a fixed travoprost/timolol combination in glaucoma

Jan. 29, 2004

Novel EP4 agonists with utility in glaucoma and bone disorders

Jan. 23, 2004

Santen and Asahi Glass claim new prostaglandin analogues for glaucoma and other ocular disorders

Jan. 22, 2004

AFP-168, a novel ocular hypotensive candidate

Jan. 20, 2004

International pivotal Trabio study completes enrollment

Jan. 14, 2004

ISV-205 limits IOP increase induced by corticosteroids

Jan. 9, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...